Tag: HY-091
AFT Pharmaceuticals spearheads progress in women’s health with Hyloris partnership
AFT Pharmaceuticals announced its partnership with Hyloris Pharmaceuticals, based in Belgium, to develop a novel treatment, HY-091, for Vulvar Lichen Sclerosus (VLS), addressing the critical need for effective solutions in an area where approved treatments are limited.
Featured Article
Why energy is becoming a strategic asset for manufacturers
Energy is no longer just a cost centre for manufacturers – it is fast becoming a strategic lever for efficiency, resilience and growth.
